Background: In 1998, the International EECP Patient Registry (IEPR) was organized to document patient characteristics, safety, and efficacy during the treatment period, and long-term outcomes. All centers with EECP facilities were invited to join the voluntary Registry. The Registry population comprises all patients starting EECP therapy for treatment of angina pectoris in participating centers.
Introduction
Enhanced external counterpulsation (EECP) is a noninvasive analogue of the intra-aortic balloon pump designed to increase myocardial perfusion pressure and decrease cardiac workload. Based on small clinical series, the Food and Drug Administration cleared EECP for the treatment of myocardial infarction, cardiogenic shock, and unstable and stable angina in March 1995. 1, 2 Since then, the use of EECP for the treatment of angina pectoris has continued to increase, based on both scientific and anecdotal evidence of efficacy in this population both in the United States and other countries. [3] [4] [5] [6] [7] The use of EECP in the treatment of patients with cardiovascular disease has been reviewed by Soran et al. 8 and by Soroff et al. 9 In 1995, a randomized trial, the Multicenter Study of Enhanced External Counterpulsation (MUST-EECP) trial was begun. 10 Enrollment was completed in 1997. In all, 139 patients with coronary artery disease and chronic stable angina pectoris were assigned at random to either full-pressure counterpulsation (Active-CP) or low-pressure counterpulsation (Sham-CP). Patients were masked to the treatment received. The Active-CP patient group showed a statistically significant post-treatment increase in exercise duration, increase in time to ST depression, and a reduction in the frequency of anginal episodes. The Sham-CP group demonstrated only an increase in exercise duration. Between-group differences were statistically different for time to ST-segment depression and angina counts.
The results of the MUST-EECP trial confirmed that EECP was a safe and effective treatment for patients with chronic angina. However, while patients in MUST-EECP had to meet strict criteria in order to be enrolled, they were not screened for anatomic suitability or vascular response to EECP, as doing so would have defeated patient masking. The trial population was also more homogeneous in demographics and disease characteristics than the wider patient community undergoing EECP for the treatment of chronic angina. Thus, a patient registry, the International EECP Patient Registry (IEPR), was initiated in 1997 to document both the safety and efficacy of EECP and the long-term outcome in a heterogeneous consecutive series of patients treated in the wider community. This report presents the methods used in this registry and the results of the first 978 patients enrolled.
Methods
Each clinical center, whether hospital based or a freestanding facility using EECP as a treatment modality, was contacted by the sponsor and invited to join the Registry. The Registry is purely voluntary, and there are no payments to either the clinical centers or patients for participation. This report describes the results obtained from the first 43 centers joining the Registry. Overall responsibility for Registry procedures and policies is governed by a Steering Committee with representatives from the clinical centers, the Coordinating Center at the University of Pittsburgh, and the sponsor (see Appendix II). All clinical centers have been approved by their Institutional Review Boards for participation in the Registry (if required), and patients in the Registry are required to give informed consent.
All Registry patients were treated with EECP ® equipment (Vasomedical, Inc., Westbury N.Y., USA) which consists of an air compressor, a control console, a treatment table, and three pairs of pneumatic cuffs. Prior to a treatment session, these cuffs are wrapped around the patient's legs and buttocks. In early diastole, pressure is applied sequentially from the lower legs to the lower and upper thighs to propel both arterial and venous blood toward the heart. The result is an increase of diastolic blood pressure (diastolic augmentation) with retrograde aortic blood flow, as well as an increase in venous return during diastole. At end diastole, air is released simultaneously from all the cuffs to remove the external applied pressure, allowing the compressed vessels to reconform, thereby reducing vascular impedance and decreasing cardiac workload. In general, treatment is applied 1 or 2 h daily, 5 or 6 days a week, for a minimum total of 35 h.
The Registry aims to collect data on as broad a range of patients as possible. The criteria for entry are only that the patient give informed consent and have at least 1 h of EECP treatment. Every center enrolls all consecutive patients entering treatment with no exclusions due to demographics, clinical status, or outcome.
Each patient is noted on a screening log maintained at the clinical centers. The logs are sent monthly via facsimile transmission to the Coordinating Center. The screening log serves as a quality control measure ensuring that the Registry records all patients being treated. Because of the voluntary nature of the Registry, care was taken while formulating the data collection methods to keep data collection simple by limiting the number of forms and data items required. Before the first hour of treatment, a one-page form is completed describing demographics, medical history, disease characteristics, and symptoms. At the last hour of treatment, another single page form is completed describing the length of treatment, the degree of diastolic augmentation achieved (the ratio of diastolic to systolic area as measured by finger plethysmography), untoward clinical events, and symptomatology. A patient is considered to have not completed a full treatment course under the following circumstances: a medical event disrupted EECP treatment, the patient chose to discontinue treatment, or the patient missed five consecutive treatments for any reason. Subsequent to the last treatment, follow-up by telephone contact occurs at 6 months, and 1, 2, and 3 years. The follow-up form records clinical events, hospitalizations, and anginal status. The patient's quality of life is assessed at each contact by means of a three-item questionnaire assessing current quality of life, health status, and satisfaction with quality of life. Each qualityof-life measure is rated by the patient on a five-point scale on which 1 represents the best and 5 the poorest rating. Each data item is defined in detail in a Manual of Operations provided to every center, and every center is trained individually for data collection by means of a telephone conference call between the Coordinating Center and the clinical center coordinators. All forms are faxed to the Coordinating Center at the University of Pittsburgh for data entry and processing.
The primary outcome measure is exertional angina status, as gauged by the Canadian Cardiovascular Society Classification. 11 Other measures include the number of angina episodes and nitroglycerin intake per week as reported by the patient. To afford insight as to whether particular categories of patients might be more or less responsive to EECP, the Registry analyzes important subgroups. For this report we compared those who were judged not suitable for revascularization by more conventional techniques such as coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI), and those who were considered suitable, but chose EECP to delay or avoid revascularization . Chi-square tests and t-tests, as appropriate, are used to compare patients who are and are not revascularization candidates. A two-sided p value of < 0.05 was deemed statistically significant.
Results
At the end of the first 18 months of operation, there were 43 centers in the Registry, including four from outside North America, with a total of 1,246 patients enrolled. A listing of centers is shown in Appendix II. Compliance has been excellent, with 98% of all pre-EECP forms and 93% of post-EECP forms having been completed. From January 1, 1998, to April 30, 1999, there were 978 patients entered into the Registry for whom data at baseline (including revascularization status) and at completion of treatment were available. These patients form the basis of this report.
Baseline Characteristics
Enhanced external counterpulsation is a therapy used primarily for treatment of chronic angina pectoris in patients who either are not suitable for more conventional forms of revascularization or have been previously revascularized but have recurrent symptoms. The characteristics of the patient population reflect this, with 671 (68.6%) considered to be not suitable candidates for conventional revascularization at the time of commencing EECP therapy. The remaining 307 patients have been judged suitable for either PCI or CABG, but have chosen EECP to avoid or postpone invasive revascularization. Of those who were candidates, 68% were regarded as suitable for PCI and 85% as suitable for CABG with 17% suitable for either procedure. The baseline characteristics of patients not candidates for revascularization were compared with suitable candidates in Tables I and II . Overall, the patients had a mean age of 66.2 years (range 31-97 years) and were most frequently white (92%) and male (76%). They had long-standing coronary disease with a mean duration since diagnosis of 9.5 years. Multivessel coronary disease was present in 78% of patients. Demographic characteristics were similar for the candidates and the noncandidates.
Over 80% of the patients had previous revascularization with either PCI or CABG, and 7% had had a previous course of treatment with EECP before the Registry was started. Other relevant medical history included a previous myocardial infarction in 68% of patients, congestive heart failure in 28%, and noncardiac vascular disease in 32%. Risk factors for coronary disease occurred with high frequency; family history of coronary artery disease in 74%, diabetes in 40%, hypertension in 68%, hyperlipidemia in 75%, and a history of smoking in 71%. It was not surprising that, compared with the candidates, the patients who were not candidates for revascularization had a more unfavorable disease profile, with significantly higher proportions having previous revascularization, prior myocardial infarction, congestive heart failure, and noncardiac vascular disease. However, the prevalences of traditional CAD risk factors were similar in the two groups.
Angina status and extent of coronary disease are shown in Table II . Over 69% of patients had Canadian Cardiovascular Society Classification (CCSC) class III or IV angina, with a mean of 8.6 episodes of angina per week. Those who were not revascularization candidates had significantly worse angina classification, significantly lower left ventricular ejection fractions, and were significantly more likely to have multivessel disease. Nitroglycerin (sublingual or spray) was used by 62% with a mean frequency of 8.8 times a week. Nitroglycerin usage was much higher in the group who were not candidates (68 vs. 50%, p < 0.001).
Quality of life at the beginning of EECP treatment was poor. Only 34% of noncandidates and 52% of revascularization candidates rated their health as good or excellent (1, 2, or 3 on the 5 point scale). This difference was statistically signif-437 icant (p < 0.001). Similar differences were seen in the quality of life rating (rated good or excellent by 48% of noncandidates vs. 65% of candidates, p < 0.001), and satisfaction with quality of life (rated good or excellent by 45% of noncandidates vs. 58% of candidates, p < 0.001).
Post EECP Results
The post EECP results for patients completing treatment are shown in Table III Table I . Table I. 85.0% for those who were candidates). Patients failed to complete treatment for a number of different reasons; a medical event occurred which disrupted EECP treatment, or the patient chose to discontinue treatment (usually due to vacation, or time pressures of work). For patients completing treatment, there was a significant difference between the two groups in the mean diastolic augmentation area ratio (diastolic/systolic area under the curve) achieved. Patients who were candidates achieved a mean area ratio of 1.5, compared with 1.2 for those not candidates, p < 0.001. However, both groups of patients reported much improved anginal functional status post EECP, as evidenced by a decrease in at least one CCSC angina class (83.5% of candidates vs. 79.8% of noncandidates, p = NS), a mean decrease in angina episodes per week (4.7 for candidates vs. 7.1% for noncandidates, p < 0.05), and a substantial decrease in use of nitroglycerin (71.1% of candidates using nitroglycerin had discontinued its use by the end of EECP, vs. 58.6% of noncandidates, p < 0.05). The change in angina class from pre-to post-EECP treatment is shown in Figure 1 for all patients completing treatment.
Quality of Life Measures Post EECP
After treatment, quality of life was ranked good or excellent by 86% of noncandidates and 92% of candidates, and satisfaction with quality of life was ranked good or excellent by 83% of noncandidates and 90% of candidates. These differences were statistically significant (p < 0.05 for all three measures). However, a more sensitive indicator of changes in quality of life is the difference in reported quality of life pre-and post-EECP treatment (as shown in Table III ). Here there were no statistically significant differences between the two groups. Overall there was an improvement in health status for 67% of patients, in quality of life for 63%, and in satisfaction with life for 67%.
Adverse Events
The overall adverse event rate was low, with only 11 patients (1.1%) reporting withdrawal from treatment because of a serious cardiac event (death, myocardial infarction, CABG, or PCI). These serious events occurred after a mean treatment time of 19 h, and none occurred within 48 h of a treatment session. Clinical events were cited as the reason for discontinuing treatment in 43.8% of the patients withdrawing. The other withdrawals were reported as being due to the patient's decision. The clinical events reported in these patients are listed in Table IV . There were no statistically significant differences between the two groups of patients. Clinical events included unstable angina (2.4%), congestive heart failure (2.1%), and myocardial infarction (0.4%). Revascularization by conventional means (CABG 0.5% and PCI 0.3%) also occurred even among those patients initially judged to be unsuitable for 439 Table I . revascularization. Events specific to EECP and that interrupted treatment included problems with skin abrasion (1.1%) and musculoskeletal problems (2.1%). The event rate for other noncardiac medical events was 5.4%.
Discussion
The results presented here represent the largest reported series of consecutive patients treated with EECP for chronic angina pectoris. These patients show a profile of long-standing coronary disease, with chronic angina unrelieved by medical means or conventional revascularization. A small number of patients presented with unstable angina, the majority of whom were not candidates for other revascularization treatment. Concomitant diseases such as congestive heart failure and diabetes were frequent. The majority of the patients were not considered candidates for conventional revascularization at the start of the EECP treatment. Of the patients considered suitable candidates many had already had either surgical or percutaneous revascularization previously. The registry collects data concerning previous revascularizations but not details regarding the outcome of procedures.
Most patients, regardless of whether or not they were considered suitable for conventional revascularization procedures, experienced relief of angina after a complete course of EECP treatment. Patients reported decreases in the number of angina episodes and use of nitroglycerin, as well as less restriction because of angina as measured by the CCSC class. Quality of life was also improved for the majority, along with this increase in angina class. These initial results from the IEPR are consistent with those obtained in previous trials and observational studies, including the findings of the MUST-EECP trial, that EECP treatment is a safe and effective method for reducing chronic angina. The fact that there were few adverse effects of EECP is important.
The results of the quality of life measures also are consistent with those of the MUST-EECP trial 12 and a previous psychosocial study that showed the considerable improvement in well being of patients after treatment with EECP. 13 In the 32% of Registry patients who were deemed to be candidates for either PCI or CABG, but had instead chosen to be treated with EECP, the majority tolerated EECP well and showed considerable reduction in angina at the end of treatment. Only three of these patients stopped EECP and underwent surgical revascularization before the completion of EECP.
Another important issue is that 15% of the patients starting EECP therapy did not complete the prescribed course of treatment. In many of these cases, interrupting noncardiac medical events caused termination of EECP treatment. Determining which patients are more likely to not complete treatment and whether these patients return to complete EECP after resolution of their medical problems, will be an important goal of the Registry. The EECP therapy, while noninvasive, is time consuming for the patient and requires daily attendance for many weeks. This can be burdensome for some patients, either because they are currently employed and cannot obtain the required leave time, or because they are dependent on others to provide transportation. The question of whether these patients subsequently return for treatment will be addressed. Furthermore, it would be important to know whether shorter intervals of EECP could be as effective in improving anginal status.
Whether the benefits of EECP persist after the end of the course of treatment and if so, for how long, is crucial. A study by Lawson et al. 2 demonstrated a 3-year sustained benefit in patients as measured by stress thallium test and anginal status, and patients at 5 years demonstrated morbidity and mortality comparable with those undergoing CABG. 14 Of the patients in the MUST-EECP trial, 70% showed quality of life benefits at 1 year. 12 The Registry will follow all patients for at least 3 years to determine whether these sustained benefits, seen in the prior studies on small numbers of patients, are replicated in everyday clinical use.
Limitations
A primary limitation of this analysis is the lack of a control group to assess the extent of the reported improvement due to other interventions or to the "placebo effect" that may be expected with a population of symptomatic patients enthusiastic about a newly emerging treatment. An observational registry study cannot directly address whether the treatment benefit observed in the MUST-EECP randomized trial extends to the entire EECP population. However, the Registry does document the safety of the approach and suggests a benefit in a wider range of patients than has been validated with randomized trials.
Conclusions
Enhanced external counterpulsation has been shown to be a safe and effective treatment for the reduction of chronic angina in a heterogeneous group of patients, including those for whom more conventional revascularization techniques are an alternative. Adverse events occur infrequently during the course of treatment. Events specifically associated with the treatment itself (musculoskeletal pains and problems with skin abrasion) also had a low rate of occurrence and infrequently were severe enough to cause discontinuation of therapy. 
